Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma

被引:15
作者
Fleuren, Emmy D. G. [1 ,2 ,3 ]
Vlenterie, Myrella [4 ]
van der Graaf, Winette T. A. [4 ,5 ]
机构
[1] UNSW Sydney, Childrens Canc Inst, Lowy Canc Res Ctr, Sydney, NSW, Australia
[2] UNSW Sydney, Sch Clin Med, UNSW Med & Hlth, Sydney, NSW, Australia
[3] UNSW Sydney, Ctr Childhood Canc Res, Sydney, NSW, Australia
[4] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[5] Erasmus MC, Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
关键词
osteosarcoma; Ewing sarcoma; tyrosine kinase; tyrosine kinase inhibitor; angiogenesis; HIGH-GRADE OSTEOSARCOMA; PHASE-II; SOLID TUMORS; DOUBLE-BLIND; PAZOPANIB; SORAFENIB; EFFICACY; SAFETY; RECURRENT; THERAPY;
D O I
10.3389/fonc.2023.1013359
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Osteosarcoma (OS) and Ewing sarcoma (ES) are the two most common types of primary bone cancer that predominantly affect the young. Despite aggressive multimodal treatment, survival has not improved significantly over the past four decades. Clinical efficacy has historically been observed for some mono-Receptor Tyrosine Kinase (RTK) inhibitors, albeit in small subsets of OS and ES patients. Clinical efficacy in larger groups of OS or ES patients was reported recently with several newer generation multi-RTK inhibitors. All these inhibitors combine a strong anti-angiogenic (VEGFRs) component with simultaneous inhibition of other key RTKs implicated in OS and ES progression (PDGFR, FGFR, KIT and/or MET). However, despite interesting clinical data, none of these agents have obtained a registration for these indications and are thus difficult to implement in routine OS and ES patient care. It is at present also unclear which of these drugs, with largely overlapping molecular inhibition profiles, would work best for which patient or subtype, and treatment resistance almost uniformly occurs. Here, we provide a critical assessment and systemic comparison on the clinical outcomes to the six most tested drugs in this field in OS and ES to date, including pazopanib, sorafenib, regorafenib, anlotinib, lenvatinib and cabozantinib. We pay special attention to clinical response evaluations in bone sarcomas and provide drug comparisons, including drug-related toxicity, to put these drugs into context for OS and ES patients, and describe how future trials utilizing anti-angiogenic multi-RTK targeted drugs could be designed to ultimately improve response rates and decrease toxicity.
引用
收藏
页数:16
相关论文
共 72 条
[51]   Pazopanib in metastatic osteosarcoma: Significant clinical response in three consecutive patients [J].
Safwat, Akmal ;
Boysen, Anders ;
Lucke, Arne ;
Rossen, Philip .
ACTA ONCOLOGICA, 2014, 53 (10) :1451-1454
[52]   Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report [J].
Sai, Satoshi ;
Imamura, Yoshinori ;
Kiyota, Naomi ;
Jimbo, Naoe ;
Toyoda, Masanori ;
Funakoshi, Yohei ;
Chayahara, Naoko ;
Hyogo, Yasuko ;
Takenaka, Kei ;
Suto, Hirotaka ;
Minami, Hironobu .
MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (01) :1-4
[53]   Genome-Informed Targeted Therapy for Osteosarcoma [J].
Sayles, Leanne C. ;
Breese, Marcus R. ;
Koehne, Amanda L. ;
Leung, Stanley G. ;
Lee, Alex G. ;
Liu, Heng-Yi ;
Spillinger, Aviv ;
Shah, Avanthi T. ;
Tanasa, Bogdan ;
Straessler, Krystal ;
Hazard, Florette K. ;
Spunt, Sheri L. ;
Marina, Neyssa ;
Kim, Grace E. ;
Cho, Soo-Jin ;
Avedian, Raffi S. ;
Mohler, David G. ;
Kim, Mi-Ok ;
DuBois, Steven G. ;
Hawkins, Douglas S. ;
Sweet-Cordero, E. Alejandro .
CANCER DISCOVERY, 2019, 9 (01) :46-63
[54]   Cabozantinib as an emerging treatment for sarcoma [J].
Schoffski, Patrick ;
Blay, Jean-Yves ;
Ray-Coquard, Isabelle .
CURRENT OPINION IN ONCOLOGY, 2020, 32 (04) :321-331
[55]   Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas [J].
Schulte, Brian ;
Mohindra, Nisha ;
Milhem, Mohammed ;
Attia, Steven ;
Robinson, Steven ;
Monga, Varun ;
Hirbe, Angela C. ;
Oppelt, Peter ;
Charlson, John ;
Helenowski, Irene ;
Abbinanti, Susan ;
Cehic, Rasima ;
Okuno, Scott ;
Van Tine, Brian A. ;
Agulnik, Mark .
BRITISH JOURNAL OF CANCER, 2021, 125 (04) :528-533
[56]  
Seto Tiffany, 2019, Med Sci (Basel), V7, DOI 10.3390/medsci7030048
[57]   Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up [J].
Strauss, S. J. ;
Frezza, A. M. ;
Abecassis, N. ;
Bajpai, J. ;
Bauer, S. ;
Biagini, R. ;
Bielack, S. ;
Blay, J. Y. ;
Bolle, S. ;
Bonvalot, S. ;
Boukovinas, I ;
Bovee, J. V. M. G. ;
Boye, K. ;
Brennan, B. ;
Brodowicz, T. ;
Buonadonna, A. ;
de Alava, E. ;
Dei Tos, A. P. ;
Del Muro, X. Garcia ;
Dufresne, A. ;
Eriksson, M. ;
Fagioli, F. ;
Fedenko, A. ;
Ferraresi, V ;
Ferrari, A. ;
Gaspar, N. ;
Gasperoni, S. ;
Gelderblom, H. ;
Gouin, F. ;
Grignani, G. ;
Gronchi, A. ;
Haas, R. ;
Hassan, A. B. ;
Hecker-Nolting, S. ;
Hindi, N. ;
Hohenberger, P. ;
Joensuu, H. ;
Jones, R. L. ;
Jungels, C. ;
Jutte, P. ;
Kager, L. ;
Kasper, B. ;
Kawai, A. ;
Kopeckova, K. ;
Krakorova, D. A. ;
Le Cesne, A. ;
Le Grange, F. ;
Legius, E. ;
Leithner, A. ;
Pousa, A. Lopez .
ANNALS OF ONCOLOGY, 2021, 32 (12) :1520-1536
[58]   Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma [J].
Subbiah, Vivek ;
Meyer, Christian ;
Zinner, Ralph ;
Meric-Bernstam, Funda ;
Zahurak, Marianna L. ;
O'Connor, Ashley ;
Roszik, Jason ;
Shaw, Kenna ;
Ludwig, Joseph A. ;
Kurzrock, Razelle ;
Azad, Nilofer A. .
CLINICAL CANCER RESEARCH, 2017, 23 (15) :4027-4034
[59]   Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma [J].
Sulzbacher, I ;
Birner, P ;
Trieb, K ;
Träxler, M ;
Lang, S ;
Chott, A .
MODERN PATHOLOGY, 2003, 16 (01) :66-71
[60]   Pazopanib maintenance therapy after tandem high-dose chemotherapy for disseminated Ewing sarcoma [J].
Tamura, Akihiro ;
Yamamoto, Nobuyuki ;
Nino, Nanako ;
Ichikawa, Takayuki ;
Nakatani, Naoko ;
Nakamura, Sayaka ;
Saito, Atsuro ;
Kozaki, Aiko ;
Kishimoto, Kenji ;
Ishida, Toshiaki ;
Yoshida, Makiko ;
Akasaka, Yoshinobu ;
Hasegawa, Daiichiro ;
Kosaka, Yoshiyuki .
INTERNATIONAL CANCER CONFERENCE JOURNAL, 2019, 8 (03) :95-100